PAA

8.89%

24.5¢ pharmaust limited

Ann: Application for quotation of securities - PAA, page-13

First 13 Last

Share
Profile

Follow
Peeteepoo

2,482 Posts.

1409

06/02/24

19:59

Post #: 72270186
Share

Originally posted by Jakjazz: ↑

Hmmmm your question raises multiple pathways but I guess does the board (with support of SHs) want a lick of the ice cream (MND) or the whole thing and when I say the whole thing, MND, canine and human cancer, neurodegenerative diseases (obviously receiving more and more attention by PAA), covid and all those other diseases tested by the Olivia Newton-John Cancer Centre.

You would think as mentioned by you that BP would want to see the Phase 2/3 results before they made a move but if the top line results are remarkable then its risk versus reward comes int play and as NZT often mentions protection by BP of their current revenue streams. My thinking therefore is if we get remarkable results then it would be no surprise for BP to seek a potential licensing arrangement of MPL for MND. Not sure a T/O would be in play due to the valuation issues related to MPL as a treatment for other diseases etc. I am sure the SH would want something to reflects MPL's potential even if not trialled. If a T/O was in play before Phase 2/3 suggest its an attempt at a "cheap charlie" price in order have access to MPL for other neurodegenerative diseases etc.

Als remember Spark provided a ~$1/per share valuation (only MND and canine cancer) as of now and as such the $1/share is heavily risked given the current state of trialling and no top line results. Should top line results be achieved then in my simple mind the $1/share would increase substantially ($1.50 - $2.00).

Anther issue is BP's revenue cliff and what areas of revenue need to be replaced. This leads me to think a licensing proposal would be likely prior to a Phase2/3. Get in early and keep the cost of licensing MPL at a minimum and before other BPs create an expensive auction for MPL.

I would hope and do expect current management to maximize the value of MPL for PAA and all SH and as such assuming top line results are remarkable then they would favour a licensing of MPL for MND while pursuing MPL as a treatment for all the various other diseases/cancer i.e. adopting a policy of monetisation of MPL through licensing arrangements. This would be the long game and SH would see (hopefully) an ever increasing SP plus dividends.

I think we should also remember a T/O may not necessarily be a cash transaction but could be equity or equity/cash. The earlier any T/O then the less likely SH will receive the full benefit from MPL as the new penicillin fr numerous diseases but there is also no certainty of future success.

Gee i could go on for ever but its easy to lose track of the thought process so better stop here for now.

I am also sure there are other more qualified HC people to opine on your questions.

Phewwwww....thats all folks!!!

Expand

Thanks JJ,
You raise some interesting and valid points. I'm very grateful MPL has proven to be an effective [Almost proved beyond doubt] neurological treatment. The Oncology field is more competitive and trials appear much more expensive and time consuming. Well they appear to be anyway.

Finger crossed, all we need is a bit of luck.

Cheers

PAA Price at posting: 17.5¢ Sentiment: Buy Disclosure: Held
10 Upvote

0 Great analysis

Reply

First 13 Last

(20min delay)
Last 24.5¢		Change 0.020(8.89%)		Mkt cap ! $96.99M

Open	High	Low	Value	Volume
22.5¢	24.5¢	22.5¢	$150.8K	649.5K

Buyers (Bids)

No.	Vol.	Price($)
2	30000	23.5¢

Sellers (Offers)

Price($)	Vol.	No.
24.5¢	50607	2

View Market Depth

No.	Vol.	Price($)
2	30000	0.235
1	50000	0.230
3	191444	0.225
2	96500	0.220
4	30744	0.215

Price($)	Vol.	No.
0.245	50607	2
0.250	69751	4
0.255	110000	1
0.260	350230	4
0.265	181000	2

Last trade - 16.10pm 17/06/2024 (20 minute delay)


Last 24.0¢		Change 0.020 ( 6.67 %)
Open	High	Low	Volume
22.5¢	24.0¢	22.5¢	231366
Last updated 15.56pm 17/06/2024 ?

PAA (ASX) Chart

Ann: Application for quotation of securities - PAA, page-13

Featured News

Construction commences on the Nobles Gold Processing Facility

Warren Tredrea on the union boss-fuelled feud threatening key AFL projects

RAU all set to samba in Brazil rare earths space off successful IPO launchpad

MiningNews Select Conference: Inflation and global shifts pose funding challenges for Aus miners

ASX Market Update: Shares slip with energy and IT in drag mode | 17 June, 2024

Buyers (Bids)

Sellers (Offers)

Featured News

Ann: Application for quotation of securities - PAA, page-13

Featured News

Top Stories

Construction commences on the Nobles Gold Processing Facility

Warren Tredrea on the union boss-fuelled feud threatening key AFL projects

RAU all set to samba in Brazil rare earths space off successful IPO launchpad

MiningNews Select Conference: Inflation and global shifts pose funding challenges for Aus miners

ASX Market Update: Shares slip with energy and IT in drag mode | 17 June, 2024

Buyers (Bids)

Sellers (Offers)

Featured News